Search hospitals > Washington > Seattle
Virginia Mason Medical Center
Claim this profileSeattle, Washington 98101
Global Leader in Lung Cancer
Global Leader in Parotid Gland Cancer
Conducts research for Prostate Cancer
Conducts research for Cancer
Conducts research for Breast Cancer
506 reported clinical trials
25 medical researchers
Summary
Virginia Mason Medical Center is a medical facility located in Seattle, Washington. This center is recognized for care of Lung Cancer, Parotid Gland Cancer, Prostate Cancer, Cancer, Breast Cancer and other specialties. Virginia Mason Medical Center is involved with conducting 506 clinical trials across 650 conditions. There are 25 research doctors associated with this hospital, such as Huong T. Pham, David Aboulafia, MD, Vincent Picozzi, MD, and Hagen F. Kennecke.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage II
Stage III
2Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Huong T. PhamVirginia Mason Medical Center1 year of reported clinical research
Studies Colorectal Cancer
Studies Lung Cancer
22 reported clinical trials
55 drugs studied
David Aboulafia, MDVirginia Mason Medical Center9 years of reported clinical research
Studies Lymphoma
Studies Kaposi's Sarcoma
12 reported clinical trials
27 drugs studied
Vincent Picozzi, MDVirginia Mason Medical Center5 years of reported clinical research
Studies Pancreatic Cancer
Studies Pancreatic Adenocarcinoma
6 reported clinical trials
17 drugs studied
Hagen F. KenneckeVirginia mason medical Center5 years of reported clinical research
Studies Colorectal Cancer
Studies Rectal Cancer
6 reported clinical trials
17 drugs studied
Clinical Trials running at Virginia Mason Medical Center
Lung Cancer
Bladder Cancer
Pancreatic Cancer
Stroke
Hearing Loss
Rectal Cancer
Parotid Gland Cancer
Cancer
Breast Cancer
Crohn's Disease
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Zolbetuximab + Chemotherapy
for Pancreatic Cancer
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to improve outcomes in people with pancreatic cancer. In this study, zolbetuximab will be given together with chemotherapy to people with pancreatic cancer. Zolbetuximab attaches to a protein called CLDN18.2 found at high levels on the surface of the cancer tumor. This switches on the immune system to attack the tumor. Adults 18 years or older with metastatic pancreatic cancer who have not previously had chemotherapy can take part in the study. There are 2 main aims of this study: * To check the safety of zolbetuximab, when given with chemotherapy in people with metastatic pancreatic cancer * To check if people could cope with (tolerate) any medical problems during the study This is an open-label study. This means people in the study and the study doctors will know that people will receive zolbetuximab with chemotherapy. Different small groups will receive lower to higher doses of zolbetuximab with chemotherapy. Zolbetuximab and chemotherapy will be given through a vein. This is called an infusion. People will receive zolbetuximab on the first day they receive chemotherapy. This will happen every 14 days in a 28-day cycle. People will receive zolbetuximab and chemotherapy in the study clinic and at home. Also, doctors will check for any medical problems. People will also have a health check including blood tests. On some visits they will also have scans to check for any changes in their cancer. People will visit the study clinic about 7 days after they stop treatment. They will be asked about any medical problems and will have a health check including blood tests. After this, people will have several more visits to the study clinic for health checks. The number of visits and checks done at each visit will depend on the health of each person and whether they complete their treatment or not.
Recruiting1 award Phase 16 criteria
Immunotherapy
for Pancreatic Cancer
This trial tests a new treatment for pancreatic cancer using a special vaccine, a virus for delivery, and an immune-boosting drug. It aims to help the immune system better fight cancer in patients whose disease has spread, is locally advanced, or has been surgically removed. Vaccine therapy is being tested for many forms of cancer, including pancreatic cancer, with early trials showing safety and some increased survival.
Recruiting1 award Phase 1
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Virginia Mason Medical Center?
Where is Virginia Mason Medical Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does Virginia Mason Medical Center accept?
What awards or recognition has Virginia Mason Medical Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.